JAKARTA - Entering 2023, Bio Farma has planned a number of things to prove itself as one of the companies that can be more reliable at the global level. The achievement of the Pharmaceutical BUMN Holding in 2022 in the COVID-19 pandemic situation is a milestone for Bio Farma's optimism.
Moreover, at this time, Bio Farma already has more than hundreds of years of experience as a pharmaceutical SOE and a life science. Therefore, they have a great desire to exceed their previous targets.
President Director of Bio Farma Honesti Basyir said, Bio Farma Group as a holding and operating company must be able to maintain this success, such as increasing value, as well as creating growth stories, so that their existence is not lost in the future.
"In 2023, the year of proof. A year to prove, a year to province! We have to prove and convince all layers of stakeholders that Bio Farma is The Dancing Giant, a big giant who has high experience," Basyir said in a written statement, Saturday, January 7.
"Instead of being consumed by time, we will transform into a leading life science company, both at the local and global levels," he added.
Throughout 2022, Bio Farma as the parent entity, as well as Kimia Farma and Indofarma as subsidiaries have faced tough challenges in contributing to national health security, including Bio Farma as an integrated Healthcare Ecosystem.
One of the moments towards the Healthcare Ecosystem was shown by the launch of the COVID-19 IndoVac vaccine which was inaugurated by President Joko Widodo at that time.
The IndoVac vaccine is one of the tangible results of the independence of the national pharmaceutical industry with TKDN of 90 percent, which has received an emergency distribution permit or EUA from BPOM in September 2022.
Around the last three years facing COVID-19, Bio Farma Group has been at the forefront of handling the pandemic in Indonesia.
Among other things, in handling and overcoming health issues in Indonesia, handling COVID-19, providing 70 percent of the global supply of polio vaccines, to retail medicines at very affordable prices.
"With the increasingly sloping number of COVID-19 cases in Indonesia, we should be proud to be able to bring Indonesia to gradually recover," Basyir said.
Still in 2022, Bio Farma Group has also increased national pharmaceutical health resilience through global collaboration, such as collaborating with the British Pharmaceutical Company and Profactor Pharma.
In this collaboration, Bio Farma has received exclusive rights to joint development of the blood product Recombinant Factor VIII (Profactor and Bio Farma) globally.
Then, the collaboration between Bio Farma with Google Cloud, Fitbit and Connectedlife on new digital health initiatives.
Furthermore, the launch of BioColomelt-Dx, a molecular diagnostic kit to detect genetic abnormalities in collectral cancer patients and the signing of cooperation with MSD (Merck & Co,m Inc. trading name, Rahway, NJ, USA) to locally produce a 4-valent vaccine human papillomavirus (HPV).
It doesn't stop there, in Indonesia, Bio Farma is the only state-owned company to receive the 2022 Primaniyarta, Top BUMN Awards, and Platinum, which is the highest level in the Asia Sustainability Reporting Rating (ASRRAT) event from the Ministry of Environment and Forestry.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
